Malignant Male Reproductive System Neoplasm

In the BRCA-altered cohort (n = 302; deleterious BRCA1/2 alterations) of the global, randomized, open-label phase III TRITON3 trial (NCT02975934) in mCRPC, pts treated with rucaparib (600 mg twice/day… (full text at CIViC)

PMID 36795891 · Fizazi et al., 2023 · Open in CIViC

In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers. Patients with BRCA1/2 mutations had a 2-fold higher … (full text at CIViC)

PMID 23569316 · Castro et al., 2013 · Open in CIViC

Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway. Platinum-based chemotherapies have shown efficacy in BRCA2-alte… (full text at CIViC)

PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC

In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In the post hoc exploratory BRCA2-only subgroup (n = 128; olaparib, n = 81; control, n = 47) of the phase III randomized open-label PROfound trial (NCT02987543), olaparib monotherapy supported Sensiti… (full text at CIViC)

PMID 37963304 · Mateo et al., 2024 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In an in vitro study using docetaxel-resistant PC-3R cells, knockdown with CD44v8-10 siRNAs increased sensitivity to docetaxel (p < 0.05) compared to negative control.

PMID 32642575 · Kato et al., 2020 · Open in CIViC

In prostate cancer models, CDK12 loss impaired homologous recombination deficiency and sensitized cells to PARP inhibitors (olaparib, rucaparib, talazoparib, veliparib) in a gene dosage-dependent mann… (full text at CIViC)

PMID 39321214 · Chou et al., 2024 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC)

Open in CIViC

Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two prostate carcinoma… (full text at CIViC)

PMID 22623731 · McCourt et al., 2012 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

Meta-analysis linking CHEK2 1100delC to a higher risk in prostate cancer ((OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) ).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis of 2 studies of CHEK2 and prostate cancer showing that the IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer.

PMID 26629066 · Wang et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)

PMID 38049622 · Fizazi et al., 2024 · Open in CIViC

Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were va… (full text at CIViC)

PMID 26261420 · Kohli et al., 2015 · Open in CIViC

The identification of tumor-suppressor genes in solid tumors by classical cancer genetics methods is difficult and slow. Nonsense-mediated RNA decay microarrays were combined with array-based compara… (full text at CIViC)

PMID 15300251 · Huusko et al., 2004 · Open in CIViC

The EphB2 gene has been implicated as a tumor suppressor gene somatically altered in both prostate cancer (PC) and colorectal cancer. A set of 341 single nucleotide polymorphisms (SNPs) encompassing … (full text at CIViC)

PMID 21603658 · Robbins et al., 2011 · Open in CIViC

In a clinical study including 144 patients, nuclear beta-2 expression is significantly correlated with decreased RFS (p < 0.01), decreased MFS (p < 0.01) and PSA failure (p < 0.01). Moreover cytoplasm… (full text at CIViC)

PMID 20501637 · Leung et al., 2010 · Open in CIViC

Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.04… (full text at CIViC)

PMID 25544710 · Qi et al., 2015 · Open in CIViC

A patient with prostate cancer with exceptional response to treatment was identified who harbored a somatic hemizygous deletion of the DNA repair gene FANCA and putative partial loss of function of th… (full text at CIViC)

PMID 26181256 · Beltran et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

243 primary PCa, 37 metastatic PCa, and 20 castration-resistant PCa (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the major… (full text at CIViC)

PMID 26891277 · Yu et al., 2016 · Open in CIViC

Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with doce… (full text at CIViC)

PMID 27153245 · Lee et al., 2016 · Open in CIViC

G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer. 49 out of 9012 male patients in the Mayo Clinic Biobank were carriers. 31% of patients were diagnose… (full text at CIViC)

PMID 26108461 · Beebe-Dimmer et al., 2015 · Open in CIViC

Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls. In a random effect model the pooled OR (3.38 (95% CI: 2.45–4.66)) of the studies suppor… (full text at CIViC)

PMID 27626483 · Zhang et al., 2016 · Open in CIViC

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resi… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

In prostate cancer cell lines with loss of the Y-linked histone demethylase KDM5D (knockdown in LNCaP and VCaP, or deletion in LNCaP-104R2 and E006AA), ATR signaling was activated, and the selective A… (full text at CIViC)

PMID 29863497 · Komura et al., 2018 · Open in CIViC

In prostate cancer (PCa) cell models (PC-3 and DU145; shRNA/siRNA knockdown of KMT2D), loss of enhancer activity markers H3K4me1/H3K27ac reduced FOXO3 protein abundance and DNA binding and suppressed … (full text at CIViC)

PMID 31232159 · Lv et al., 2019 · Open in CIViC

Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (… (full text at CIViC)

PMID 26892177 · Yin et al., 2016 · Open in CIViC

293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to gen… (full text at CIViC)

PMID 23329234 · Fisher et al., 2013 · Open in CIViC

One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11 gene and showed clinical response to PARP inhibitor olaparib.

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

The molecular differences between MSI-H/dMMR and TMB-H/MSS prostate cancer were studied for the impact of these differences on immune checkpoint blockade (ICB) sensitivity. MSI and TMB were studied to… (full text at CIViC)

PMID 38949888 · Lenis et al., 2024 · Open in CIViC

Study of 1817 prostate adenocarcinoma cases and 2026 cancer free controls to clarify the association of (MTHFR)c.677C>T (and c.1298A>C ) of prostate cancer risk in a population of Han Chinese in Shang… (full text at CIViC)

PMID 27819322 · Wu et al., 2016 · Open in CIViC